Allspring Global Investments Holdings LLC Sells 69,820 Shares of Progyny, Inc. (NASDAQ:PGNY)

Allspring Global Investments Holdings LLC lessened its holdings in Progyny, Inc. (NASDAQ:PGNYGet Rating) by 80.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 17,194 shares of the company’s stock after selling 69,820 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Progyny were worth $637,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. National Bank of Canada FI bought a new stake in Progyny in the 2nd quarter valued at $29,000. Lazard Asset Management LLC bought a new position in Progyny during the 1st quarter worth $62,000. Parkside Financial Bank & Trust bought a new position in Progyny during the 1st quarter worth $70,000. Captrust Financial Advisors increased its position in Progyny by 25.0% during the 1st quarter. Captrust Financial Advisors now owns 2,091 shares of the company’s stock worth $107,000 after buying an additional 418 shares during the period. Finally, Castle Wealth Management LLC bought a new position in Progyny during the 2nd quarter worth $63,000. Institutional investors own 86.12% of the company’s stock.

Insider Activity at Progyny

In related news, CEO Peter Anevski sold 34,385 shares of the firm’s stock in a transaction dated Tuesday, October 25th. The stock was sold at an average price of $39.76, for a total value of $1,367,147.60. Following the sale, the chief executive officer now directly owns 250,445 shares of the company’s stock, valued at $9,957,693.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Peter Anevski sold 34,385 shares of Progyny stock in a transaction dated Tuesday, October 25th. The stock was sold at an average price of $39.76, for a total transaction of $1,367,147.60. Following the sale, the chief executive officer now directly owns 250,445 shares of the company’s stock, valued at $9,957,693.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Mark S. Livingston sold 14,801 shares of Progyny stock in a transaction dated Tuesday, November 29th. The shares were sold at an average price of $36.70, for a total value of $543,196.70. Following the sale, the chief financial officer now directly owns 63,994 shares in the company, valued at $2,348,579.80. The disclosure for this sale can be found here. Insiders have sold 123,966 shares of company stock valued at $4,787,473 over the last ninety days. 14.00% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have weighed in on PGNY. SVB Leerink reiterated a “market perform” rating and set a $34.00 price objective (down previously from $59.00) on shares of Progyny in a research report on Thursday, January 5th. JPMorgan Chase & Co. decreased their price target on Progyny from $78.00 to $62.00 and set an “overweight” rating on the stock in a research report on Friday, November 18th. KeyCorp decreased their price target on Progyny from $55.00 to $45.00 and set an “overweight” rating on the stock in a research report on Monday, December 19th. Finally, TheStreet upgraded Progyny from a “d+” rating to a “c” rating in a research report on Monday, October 24th. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $49.25.

Progyny Stock Down 0.8 %

NASDAQ:PGNY opened at $33.02 on Monday. The stock’s 50-day simple moving average is $32.68 and its 200 day simple moving average is $36.37. The firm has a market capitalization of $3.07 billion, a PE ratio of 78.62, a price-to-earnings-growth ratio of 4.22 and a beta of 1.59. Progyny, Inc. has a twelve month low of $25.67 and a twelve month high of $53.10.

Progyny (NASDAQ:PGNYGet Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.08. The business had revenue of $205.37 million for the quarter, compared to analyst estimates of $194.41 million. Progyny had a return on equity of 14.14% and a net margin of 6.00%. On average, analysts anticipate that Progyny, Inc. will post 0.29 EPS for the current fiscal year.

About Progyny

(Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Featured Articles

Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNYGet Rating).

Institutional Ownership by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.